Neurology

Therapies for neurological conditions including epilepsy, multiple sclerosis, ALS, and neuromuscular diseases.

Companies

Pipeline Drugs

781

Key People

1256

Neurology Pipeline (781 drugs)

Approved: 136Commercial: 99Phase 2: 70Preclinical: 66Phase 3: 65Phase 1: 44Approved/Commercial: 38Pre-clinical: 33Phase 1/2: 32Discovery: 14Phase 2/3: 13Pending Approval: 11Research: 10Development: 10Not Specified: 8Not Disclosed: 8Phase 2b: 6Various: 5Preclinical/Phase 1: 5Discovery/Preclinical: 5Pre-clinical Tool: 5Clinical Development: 4Filed/Approved: 4Phase II: 4Clinical Expansion: 4Phase 2a: 3Phase 1b/2a: 3Commercial (RUO): 3Pre-IND: 3All Phases: 3ANDA Filed: 2Clinical Evaluation: 2Phase 1b: 2Undisclosed: 2Pre-Clinical: 2Various (Typically Phase 2-4): 2R&D: 2FDA Cleared: 2Approved (KZ) / Pre-market (US): 2Multiple Phases: 1NDA Review: 1Pre-clinical/Clinical: 1Clinical: 1Phase 2b/3: 1Research/Discovery: 1OTC: 1Filed/Development: 1Development/Filed: 1Phase III: 1Launched: 1Development & Commercial: 1Preclinical/Formulation: 1Discovery to Preclinical: 1Filed: 1Filed (EU): 1Phase 1/2a: 1Marketed: 1Clinical Trials: 1Research & Development: 1Clinical/Regulatory: 1Commercial/IVD Development: 1Commercial (IVD): 1Phase 1 (inferred): 1NDA/BLA Filed: 1Preclinical/Clinical: 1Emergency Use Authorization: 1Pivotal Trial: 1Pre-Registration: 1Formulation Development: 1Approved/Procedure: 1Validation: 1Implementation: 1Pre-clinical/Development: 1Commercial Tool: 1Service Offering: 1N/A (Diagnostic): 1Pilot/Phase 2: 1Screening/Diagnostic: 1Various (Typically Phase 3): 1Under Review: 1Research Use Only: 1Not Disclosed (Likely Pre-clinical): 1Research & Regulated Studies: 1Clinical Trial: 1Development / Pilot: 1Commercial (ex-US) / Pre-market (US): 1Preclinical/Phase 1 planning: 1Phase 2 (planned): 1

Drug	Company	Indication	Phase	Status
Patisiran (ONPATTRO)	Alnylam Pharmaceuticals	Hereditary Transthyretin Amyloidosis	Approved	Commercial
Givosiran (GIVLAARI)	Alnylam Pharmaceuticals	Acute Hepatic Porphyria	Approved	Commercial
Lumasiran (OXLUMO)	Alnylam Pharmaceuticals	Primary Hyperoxaluria Type 1	Approved	Commercial
Inclisiran (LEQVIO)	Alnylam Pharmaceuticals	Hypercholesterolemia	Approved	Commercial - Partnered
Vutrisiran	Alnylam Pharmaceuticals	Hereditary Transthyretin Amyloidosis	Phase 3	Active
ALN-AGT01	Alnylam Pharmaceuticals	Hypertension	Phase 1	Active
ALN-KHK	Alnylam Pharmaceuticals	Primary Hyperoxaluria	Phase 3	Active
ALN-APP	Alnylam Pharmaceuticals	Alzheimer's Disease	Phase 1	Active
Cemdisiran	Alnylam Pharmaceuticals	C5 Complement-mediated Diseases	Phase 2	Active
Bimekizumab (Bimzelx)	UCB	Psoriatic Arthritis	Approved	Commercial
Bimekizumab	UCB	Ankylosing Spondylitis	Phase 3	Active
UCB0107	UCB	Parkinson's Disease	Phase 1	Active
Rozanolixizumab	UCB	Myasthenia Gravis	Phase 3	Active
UCB4144	UCB	Epilepsy	Phase 2	Active
UCB5857	UCB	Systemic Lupus Erythematosus	Phase 2	Active
Padsevonil	UCB	Focal Seizures	Phase 3	Active
UCB0022	UCB	Alzheimer's Disease	Phase 1	Active
Keppra (levetiracetam)	UCB	Epilepsy	Approved	Commercial
Cimzia (certolizumab pegol)	UCB	Inflammatory Diseases	Approved	Commercial
Vimpat (lacosamide)	UCB	Seizure Disorders	Approved	Commercial
Hemlibra (emicizumab)	Chugai Pharmaceutical	Hemophilia A	Approved	Commercial
Tecentriq (atezolizumab)	Chugai Pharmaceutical	Multiple Cancers	Approved	Commercial
Kadcyla (T-DM1)	Chugai Pharmaceutical	HER2+ Breast Cancer	Approved	Commercial
Phesgo	Chugai Pharmaceutical	HER2+ Breast Cancer	Approved	Commercial
Herceptin (trastuzumab)	Chugai Pharmaceutical	HER2+ Cancers	Approved	Commercial
Avastin (bevacizumab)	Chugai Pharmaceutical	Multiple Cancers	Approved	Commercial
Actemra (tocilizumab)	Chugai Pharmaceutical	Rheumatoid Arthritis	Approved	Commercial
Satralizumab	Chugai Pharmaceutical	Neuromyelitis Optica	Approved	Commercial
Crovalimab	Chugai Pharmaceutical	Paroxysmal Nocturnal Hemoglobinuria	Phase 3	Active
GYM329	Chugai Pharmaceutical	Spinal Muscular Atrophy	Phase 2	Active
Tiragolumab	Chugai Pharmaceutical	Cancer combination therapy	Phase 3	Active
Ilumya (tildrakizumab)	Sun Pharmaceutical	Psoriasis	Approved	Commercial
CEQUA (cyclosporine)	Sun Pharmaceutical	Dry Eye Disease	Approved	Commercial
Absorica/Absorica LD	Sun Pharmaceutical	Severe Acne	Approved	Commercial
Levulan Kerastick	Sun Pharmaceutical	Actinic Keratosis	Approved	Commercial
Biosimilar Portfolio	Sun Pharmaceutical	Various Oncology/Autoimmune	Phase 3	Development
SCD-044	Sun Pharmaceutical	Psoriasis	Phase 2	Active
Generic Pipeline	Sun Pharmaceutical	Multiple	Various	Ongoing
Abilify (aripiprazole)	Otsuka Holdings	Schizophrenia, Bipolar Disorder	Commercial	Marketed
Rexulti (brexpiprazole)	Otsuka Holdings	Major Depressive Disorder, Schizophrenia	Commercial	Marketed
Abilify Maintena	Otsuka Holdings	Schizophrenia, Bipolar I Disorder	Commercial	Marketed
OPC-64005	Otsuka Holdings	Alzheimer's Disease Psychosis	Phase 3	Active
Centanafadine	Otsuka Holdings	ADHD	Phase 3	Active
OPC-34712	Otsuka Holdings	Major Depressive Disorder	Phase 2	Active
Nuedexta (AVP-923)	Otsuka Holdings	Pseudobulbar Affect	Commercial	Marketed
Jynarque/Jinarc (tolvaptan)	Otsuka Holdings	ADPKD	Commercial	Marketed
LONSURF	Otsuka Holdings	Colorectal Cancer	Commercial	Marketed
Humira	Royalty Pharma	Autoimmune disorders	Commercial	Active
Imbruvica	Royalty Pharma	Blood cancers	Commercial	Active
Spinraza	Royalty Pharma	Spinal muscular atrophy	Commercial	Active